EQS — News: mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide

EQS-News: mAbxience / Key word(s): Agreement/Miscellaneous mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide 18.09.2026 / 12:35 CET/CEST The issuer is solely responsible for the content of this announcement. ══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════ • mAbxience and Sandoz have entered into a collaboration agreement combining mAbxience's development and manufacturing expertise with Sandoz's global commercial capabilities for a proposed emicizumab biosimilar candidate. • Emicizumab biosimilar expands mAbxience's pipeline into haemophilia A and strengthens its presence in rare diseases. • The agreement is consistent with mAbxience's strategy of broadening patient access to high-quality biologic medicines through selected partnerships in global markets. MADRID, Sept. 18, 2026 // — mAbxience, a majority-owned company of Fresenius SE & Co. KGaA (XETR: FRE) (OTCM: FSNUY) with partial ownership from Insud Pharma; and Sandoz (SIX: SDZ) (OTCQX: SDZNY), the global leader in affordable medicines, today announced a licensing, developme